Skip to main content
HEALIOS K.K. logo

HEALIOS K.K. — Investor Relations & Filings

Ticker · 4593 ISIN · JP3835100003 LEI · 3538005FFIDTDLUZOE53 T Professional, scientific and technical activities
Open in API
Filings indexed 74 across all filing types
Latest filing 2024-08-13 Regulatory Filings
Country JP Japan
Listing T 4593

About HEALIOS K.K.

https://www.healios.co.jp/en/

Healios K.K. is a clinical-stage biotechnology company specializing in the research and development of regenerative medicine and cell-based therapies. The company's pipeline is focused on addressing unmet medical needs in multiple therapeutic areas. Its lead programs include an allogeneic stem cell product in late-stage clinical development for ischemic stroke and Acute Respiratory Distress Syndrome (ARDS). Healios also leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop next-generation treatments. This platform includes retinal pigment epithelium (RPE) cells for age-related macular degeneration and engineered natural killer (eNK) cells designed to target solid tumors. A key area of its research is the creation of Universal Donor Cells (UDCs) to produce hypoimmunogenic therapies.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details a significant event that has a material impact on the consolidated financial condition, operating results, and cash flow, specifically mentioning the recognition of financial revenue and expenses (including derivative valuation losses and profit/loss transfers related to the Saisei Fund) for the interim consolidated accounting period ending December 2024. This structure—a formal, timely disclosure of a significant, non-periodic financial event—is characteristic of an extraordinary report in the Japanese regulatory context. Since there is no direct equivalent code for a Japanese 'Timely Disclosure Report' (TDs) that isn't a standard periodic filing (like 10-K or IR), and it reports on a significant financial event that is not a standard earnings release (ER) or a full interim report (IR), the most appropriate general category for significant, non-standard regulatory disclosures is 'Regulatory Filings' (RNS), as it serves as a catch-all for material, unscheduled events not covered by other specific codes. The document length is short (1523 chars), but it is the report itself, not an announcement of a report, so RPA is not appropriate.
2024-08-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is titled "第２四半期報告書" (Second Quarter Report) and explicitly mentions the period covered: "第14期中間期（自 2024年１月１日 至 2024年６月30日）" (14th Fiscal Year Interim Period (From January 1, 2024, to June 30, 2024)). It includes a confirmation statement by the CEO and CFO regarding the appropriateness of the filing content based on the Financial Instruments and Exchange Act. This structure strongly indicates a comprehensive financial report for an interim period shorter than a year, which corresponds to the definition of an Interim / Quarterly Report (IR). The document length is very short (591 chars), but the content is the substance of the required confirmation for the interim report, not just an announcement of its publication. Therefore, IR is the most appropriate classification.
2024-08-13 Japanese
半期報告書－第14期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for the company '株式会社ヘリオス' (Healios K.K.) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management analysis (MDA), and business updates, which are characteristic of an interim/quarterly report under Japanese financial disclosure regulations (Financial Instruments and Exchange Act). H1 2024
2024-08-13 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. The submission reason explicitly states that an event significantly impacting the consolidated financial condition, operating results, and cash flows has occurred, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details specific financial events that occurred during the first quarter of the fiscal year ending December 2024, including the recognition of financial revenue (profit transfer from the Saisei Fund) and financial expenses (derivative valuation loss, securities valuation loss, stock acquisition right issuance costs). This structure—a formal, timely disclosure triggered by a significant, non-periodic financial event—is characteristic of an extraordinary report in the Japanese regulatory context. Since there is no direct equivalent code for a Japanese 'Timely Disclosure Report' (which often covers material events outside of routine filings like 10-K or quarterly reports), the most appropriate fallback category for a significant, non-routine regulatory filing that doesn't fit other specific definitions (like M&A, Dividend, or Management Change) is the general Regulatory Filings category (RNS).
2024-05-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references '金融商品取引法第24条の４の８第１項' (Article 24-4-8, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of the quarterly report, rather than being the quarterly report itself. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS). Q1 2024
2024-05-13 Japanese
四半期報告書－第14期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the first quarter of the 14th fiscal year (January 1, 2024, to March 31, 2024) filed by Healios K.K. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis (MD&A), and business updates, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-13 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.